Aħbarijiet

  • Coronavirus disease (COVID-19): Similarities and differences with influenza

    Coronavirus disease (COVID-19): Similarities and differences with influenza

    As the COVID-19 outbreak continues to evolve, comparisons have been drawn to influenza. Both cause respiratory disease, yet there are important differences between the two viruses and how they spread. This has important implications for the public health measures that can be implemented to respo...
    Aqra iktar
  • SARS-CoV-2 Real-time RT-PCR Detection Kit

    SARS-CoV-2 Real-time RT-PCR Detection Kit

    This kit is intended for in vitro qualitative detection of ORF1ab and N genes from the 2019-nCoV in pharyngeal swab or bronchoalveolar lavage specimens collected from Coronavirus disease 2019 (COVID-19) suspected cases, suspected clusters of cases, or other individuals who need 2019- nCoV infecti...
    Aqra iktar
  • Declaration of counterfeiting our company’s brand

    Declaration of counterfeiting our company’s brand

    Aqra iktar
  • TESTSEALABS  is   ready   for  the fight  across the country  against  the new  Coronavirus (COVID-19)

    TESTSEALABS is ready for the fight across the country against the new Coronavirus (COVID-19)

    In late June 2020, due to the emergence of a new epidemic in Beijing, the prevention and control of new coronavirus in China suddenly became tense. The leaders of the central government and Beijing have reviewed the situation and formulated a meticulous anti-epidemic and...
    Aqra iktar
  • Market statement for covid-19 from testsealabs

    Market statement for covid-19 from testsealabs

    Marketing statement for covid-19 test To whom it may concern: We, Hangzhou Testsea Biotechnology Co., Ltd. (Address: Building 6 north, No. 8-2 Keji Road, Yuhang District, 311121 Hangzhou, Zhejiang Province, People’s Republic Of China) We hereby declare that any act of selling the covid-19 t...
    Aqra iktar
  • Qattiela kontra s-SARS-COV-2 flimkien

    Qattiela kontra s-SARS-COV-2 flimkien

    Taqbida kontra s-SARS-COV-2 flimkien Fil-bidu tal-2020, raġel mhux mistieden kiser il-prosperità tas-Sena l-Ġdida biex jieħu l-aħbarijiet madwar id-dinja - SARS-COV-2. Sars-cov-2 u koronavirus ieħor għandhom rotta ta 'trasmissjoni simili, prinċipalment permezz ta' qtar respiratorju u ta 'kuntatt. Komuni ...
    Aqra iktar
  • Taf kif jaħdem kit ta 'test rapidu?

    Taf kif jaħdem kit ta 'test rapidu?

    L-immunoloġija hija suġġett kumpless li fih ħafna għarfien professjonali. Dan l-artikolu għandu l-għan li jintroduċi biex il-prodotti tagħna jużaw lingwaġġ intelliġibbli iqsar. Fil-qasam ta 'skoperta rapida, l-użu fid-dar normalment juża metodu deheb kollojdali. In-nanopartiċelli tad-deheb huma faċilment konjugati ma ’antibodie ...
    Aqra iktar
  • Rakkomandazzjonijiet innovattivi tal-WHO għall-ittestjar tal-HIV għandhom l-għan li jespandu l-kopertura tat-trattament

    L-Organizzazzjoni Dinjija tas-Saħħa (WHO) ħarġet rakkomandazzjonijiet ġodda biex tgħin lill-pajjiżi jilħqu t-8.1 miljun persuna li jgħixu bl-HIV li għad iridu jiġu djanjostikati, u li għalhekk ma jistgħux jiksbu trattament għas-salvataġġ. "Il-wiċċ ta 'l-epidemija ta' l-HIV inbidel b'mod drammatiku matul l-aħħar għaxar snin, ...
    Aqra iktar

Send your message to us:

Ikteb il-messaġġ tiegħek hawn u ibgħatilna